By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Purdue Pharma L.P. et al. v. Sandoz Inc.
1:12-cv-00897; filed February 3, 2012 in the Southern District of New York
• Plaintiffs: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes Technologies, Board of Regents of the University of Texas Systems, Grunenthal GMBH
• Defendant: Sandoz Inc.
Infringement of U.S. Patent Nos. 6,488,963 ("Hot-Melt Extrudable Pharmaceutical Formulation," issued December 3, 2002), 7,674,799 ("Oxycodone Hydrochloride Having Less Than 25 PPM 14-Hydroxycodeinone," issued March 9, 2010), 7,674,800 (same title, issued March 9, 2010), 7,683,072 (same title, issued March 23, 2010), and 7,776,314 ("Abuse-Proofed Dosage System," issued August 17, 2010) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.
Shire LLC et al. v. Mylan Pharmaceuticals, Inc. et al.
2:12-cv-00638; filed February 2, 2012 in the District Court of New Jersey
• Plaintiffs: Shire LLC; Shire Development Inc.
• Defendants: Mylan Pharmaceuticals, Inc.; Mylan Inc.; Johnson Matthey Pharmaceutical Materials; Johnson Matthey Inc.
Infringement of U.S. Patent Nos. Nos. 7,105,486 ("Abuse-resistant Amphetamine Compounds," issued September 12, 2006), 7,223,735 ("Abuse Resistant Lysine Amphetamine Compounds," issued May 29, 2007), 7,655,630 ("Abuse-Resistant Amphetamine Prodrugs," issued February 2, 2010), 7,659,253 (same title, issued February 9, 2010), 7,659,254 (same title, issued February 9, 2010), 7,662,787 ("Abuse Resistant Lysine Amphetamine Compounds," issued February 16, 2010), 7,671,030 ("Abuse-Resistant Amphetamine Prodrugs," issued on March 2, 2010), 7,671,031 (same title, issued on March 2, 2010), 7,674,774 (same title, issued on March 9, 2010), 7,678,770 (same title, issued on March 16, 2010), 7,678,771 (same title, issued on March 16, 2010), 7,687,466 (same title, issued on March 30, 2010), 7,687,467 (same title, issued on March 30, 2010), 7,718,619 (same title, issued on May 18, 2010), and 7,723,305 (same title, issued on May 25, 2010) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Shire's Vyvanse® (lisdexamfetamine dimesylate, used to treat Attention Deficit Hyperactivty Disorder). View the complaint here.
Very nice venture. It simplifies tracking.
Posted by: Girish MALHOTRA | February 13, 2012 at 06:16 AM